The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary expertise in development and manufacturing capabilities. With the number of approved biosimilars ever increasing, the biopharmaceutical space is set to become more competitive for both innovator and biosimilar companies. As such, it is paramount that biosimilar and innovator companies have well-defined strategies to maximize their competitiveness. In this content, we assess strategies—based on actual practices—that companies can use to flourish in competitive global markets.
The product profiles of the biosimilars that have launched or will soon enter the major markets (United States, EU and Japan) are included in the section “Biosimilar Profiles”. These profiles include information about the biosimilar developer(s) and marketer(s), regulatory timelines, development history, approved indications, summary of clinical development, and position in the market.
Questions answered in this report:
Key markets covered:
Key companies mentioned:
Key drugs mentioned: